News about Market

Revenue of Indian Pharmaceutical Firms to Grow by 7-9 Percent in FY2024, Reports ICRA

USFDA inspections have gained momentum in the recent past and regulatory risks remain a key monitorable.

Market | 26/07/2023 | By Manvi |  1334

SPC Life Sciences files DRHP with SEBI

The company plans to raise funds through an initial public offering.

Market | 30/03/2023 | By Manvi |  931

BAL Pharma posts Rs 700.71 M revenue for Q1FY23

Revenue was impacted by macro and uncontrolled factors led by geopolitical concerns, external market turmoil and certain other unavoidable market factors

Market | 16/08/2022 | By Sudeep Soparkar |  883

Cadila Pharmaceuticals creates ? Collaboration Vertical ? to drive synergies, growth

The new vertical will work in close collaboration with different verticals of the company and group

Market | 09/08/2022 | By Sudeep Soparkar |  1925

Sebi approves for Rs 600 crores IPO to Hexagon Nutrition

It said that the company had filed its draft prospectus in December 2021. The IPO consists of a fresh issue of shares worth Rs 100 crores and an Offer For Sale (OFS) of up to 30,113,918 equity shares, as per the company's Draft Red Herring Prospectus (DRHP)

Market | 08/03/2022 | By Darshana |  648

Panacea Biotec's domestic formulation brands for India & Nepal bought by Mankind Pharma

Mankind Pharma Limited, India's 4th largest pharmaceutical company, announced that the company has entered into an agreement with Panacea Biotec to acquire the domestic formulations brands of PBPL for India and Nepal for Rs. 1,872 crore

Market | 01/03/2022 | By Darshana |  967

Mankind Pharma enters into an agreement with Dr Reddy's Laboratories Ltd to acquire two of its brands Combihale and Daffy

Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease. The market for this category is valued at ~ Rs. 900 crore growing at 14% (IQVIA). The acquisition of Combihale is expected to strengthen Mankind's presence in the inhalation respiratory market segment

Market | 16/02/2022 | By Darshana |  1236

JB Chemicals and Pharmaceuticals: revenue growth of 10 per cent

JB Chemicals and Pharmaceuticals has announced its financial results for the third quarter ended 31st December, 2021. For the third quarter ended 31st December, 2021, the company recorded revenue of Rs 601 crores as compared to Rs 548 crores, registering a growth of 10 per cent over the corresponding quarter of the previous financial year

Market | 15/02/2022 | By Darshana |  604

Cipla to acquire stake in solar power firm AMP Energy Green Eleven Pvt Ltd

Cipla has entered into a shareholder's agreement along with the power purchase agreement to acquire up to 32.49 per cent stake on a fully diluted basis in AMP Energy Green Eleven.

Market | 08/02/2022 | By Darshana |  481

Pharma Expert's take on Budget 2022

While the government has increased overall budget expenditure for healthcare and pharma industry, industry people have many insights to share on what they think about the budget 2022

Market | 02/02/2022 | By Darshana |  547